Kornimate/medical-research-clean huggingface dataset:
fascia release techniques applied to plantar flexor muscles and acute efficacy of kinesio taping

Conditions: Balance; Distorted; Fascia; Anomaly

Summary: the aim of this study; the aim of this study is to examine the effects of kinesio taping technique and percussive massage technique applied to plantar flexor muscles on proprioception, balance and flexibility in healthy individuals.

the sample of the study will consist of healthy individuals who have not had any discomfort or surgical operation related to the lower extremity in the last 6 months. the demographic information of the individuals who agreed to participate in the study will be recorded and their written consent will be obtained. participants will be divided into 2 groups as kinesio taping and percussive massage groups by randomization method. the dominant lower extremities of both groups will be applied. the percussive massage group will be applied to the posterior part of the sural fascia for 5 minutes, 3 times a week, including the plantar flexor muscles. in the kinesio taping group, taping will be done in accordance with the fascia correction technique, including the plantar flexor muscles, and it will be requested to stay for 3 days. both groups will be evaluated before and after the application. joint position sense test will be used to evaluate proprioception. in the evaluation of balance, the one-leg standing test will be considered. in the evaluation of flexibility; the flexibility of the hamstring, gastrocnemius, and plantar fascia will be examined. the straight leg lift test will be performed to look at the flexibility of the hamstring muscle. pre- and post-intervention data were statistically analyzed and compared.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study * being between the ages of 18 and 60 exclusion criteria: * injury or surgery involving the lower extremity in the last 6 months * having had an operation * malignancy, aneurysm, fever, infection, fracture, osteoporosis, rheumatoid arthritis, diabetes, * coagulation disorder etc. myofascial release techniques are contraindicated * have ailments * having any disorder that will affect balance

Keywords: proprioception flexibility balance
muscle mass and strength as predictors of time to discharge in patients with covid-19

Conditions: SARS-CoV 2

Summary: the severe acute respiratory syndrome induced by the new coronavirus (sars-cov-2) has been declared a worldwide pandemic. identifying common characteristics of the disease is crucial to promote a better prognosis for patients and to reduce the occurrence of medical complications, the time to medical discharge and mortality rates. muscle mass and strength are recognized predictive measures of medical complications and mortality in different populations, but it is still unclear whether these also applies to patients with sars-cov-2. therefore, this study will investigate whether muscle mass and/or muscle strength are predictors of the time until medical discharge of patients hospitalized with sars-cov-2. our working hypothesis is that muscle mass and/or muscle strength are predictive measurements of the time until medical discharge of patients hospitalized with sars-cov-2

muscle mass (via ultrasound) and muscle strength (via handgrip) of patients with sars-cov-2 will be assessed upon admission, medical discharge and 180 days after medical discharge. the time until medical discharge and any medical complications will be recorded. throughout the hospitalization period, the mortality rate will also be assessed. one hundred and eighty days after medical discharge, the number of hospital readmissions, mortality rate and the use of public health services will be evaluated, to estimate the cost of each patient to the health service. patients will be stratified according to muscle mass and strength assessed at admission. data will be analysed using a mixed model with repeated measures assuming group (percentiles) and time (admission, medical discharge, and 180 days after medical discharge) for each dependent variable. in the event of a significant f-value, tukey-kramer post hoc adjustments will be used for multiple purposes. survival rate will be examined using the kaplan-meier curve and analyzed using the log-rank test (mantel-cox). the level of significance will be set apriori at p≤0.05.

Eligibility criteria:
inclusion criteria: * 18 years and older ; * hospital stay less than 48 hours; * length of hospital stay to 48 hours no requiring invasive mechanical ventilation; exclusion criteria: * cancer in the last 5 years; * delirium; * cognitive deficit that impossibility the patient to read and sign the informed consent form; * neurological disease; * degenerative muscular disease.
social norms and priming to improve adherence to antiretroviral therapy and retention in care

Conditions: HIV Infection; Adherence

Summary: interventions incorporating constructs from behavioral economics and psychology have the potential to enhance hiv 'treatment as prevention' (tasp) strategies. to test this hypothesis, the investigators evaluated a combination intervention to improve antiretroviral therapy (art) adherence based on the concepts of social norms and priming.

the investigators conducted a quasi-experimental pilot study of a combination behavioral intervention based on the concepts of social norms and priming. the intervention included visual feedback about clinic-level retention in care, a self-relevant prime, and useful take-home items with the priming image. the intervention was developed using tools from marketing research and patient-centered design. the hypothesis was that the intervention would improve retention in care and adherence to art among patients living with hiv infection (plhiv). the intervention was implemented at two hiv primary clinics in shinyanga, tanzania in 2-week intervals for six months. the investigators reviewed medical records of a random sample of exposed and unexposed adult plhiv to compare retention and the proportion of patients with medication possession ratio (mpr) ≥95% after six months.

Eligibility criteria:
inclusion criteria: 1. at least 18 years of age 2. living with hiv infection 3. receiving hiv primary care at one of the two study clinics
bacterial decolonization plus intraoperative angiography for soft tissue sarcomas receiving preoperative radiotherapy (concerto)

Conditions: Sarcoma,Soft Tissue

Summary: this trial will investigate the combination of two low-cost, non-toxic strategies to assess whether they can reduce the risk of acute major wound complications in soft tissue sarcoma of the lower extremity. intranasal mupirocin ointment twice daily and chlorhexidine body cleanser once daily for 5 days prior to radiation therapy and repeated for 5 days every 2 weeks during radiation therapy may significantly reduce the risk of acute radiation dermatitis. that, along with use of indocyanine green (icg) angiography at the time of wound closure.

strategies to reduce the risk of acute wound complications have historically been mostly unsuccessful. in soft tissue sarcomas, a prior study showed that the use of indocyanine green (icg) angiography at the time of wound closure was associated with a reduction in wound dehiscence and infection when compared to historical controls. cutaneous colonization of s. aureus has been implicated in severe cases of radiation dermatitis. some known risk factors for acute major wound complications for patients with sarcomas are anatomic location in the lower extremity, preoperative radiation therapy, larger tumors, comorbidities (e.g., diabetes mellitus, tobacco usage, vascular disease, and obesity), tumors \<3mm from skin surface, and the development of grade ≥ 2 acute radiation dermatitis. both large tumors and lower extremity location can increase the likelihood of seroma formation, which can act as a nidus for infection and subsequent wound complication. rationale for this trial includes prior studies of treating patients with a bacterial decolonization (bd) protocol of intranasal mupirocin ointment twice daily and chlorhexidine body cleanser once daily for 5 days prior to rt and repeated for 5 days every 2 weeks during radiation therapy that show significantly reduced risk of acute radiation dermatitis.

Eligibility criteria:
inclusion criteria: 1. eastern cooperative oncology group (ecog) performance status (ps) 0-2 2. newly diagnosed soft tissue sarcoma arising from the lower extremity (defined as the tumor center arising at the level of the iliac crest or below) 3. eligible for wide local excision 4. eligible for external beam radiation therapy 5. negative serum pregnancy test for women of childbearing potential \< 28 days prior to rt. 6. informed consent signed and dated to participate in the study. 7. willingness and ability to comply exclusion criteria: 1. allergy to mupirocin and/or chlorhexidine 2. active dermatologic condition in rt field 3. tumor size \> 32cm 4. prior rt overlapping with fields 5. concurrent/prior invasive malignancy that could potentially interfere with proposed treatment. individual cases can be discussed with pi prior to registration

Keywords: bacterial decolonization (bd) external beam radiotherapy (rt) wide local excision (wle) intraoperative iicg angiography
immunogenicity of 2 versus 3 doses of combined hepatitis b vaccines in 2-18 months old children

Conditions: Hepatitis B

Summary: the main objective of this study is to compare the immunogenicity of the hepatitis b component in children vaccinated with (i) two doses of infanrix-hexa administered at 2 and 12 months of age versus (ii) one dose of infanrix-hexa and one dose of twinrix administered respectively at 2 and 12 months of age versus (iii) three doses of infanrix-hexa administered at 2, 4 and 18 months of age (comparator).

in the province of quebec, canada, hepatitis b vaccination of infants involves three doses of vaccine, 2, 4 and 18 months of age. however, in the current epidemiological context (virtual absence of new cases in young quebecers) and taking into account scientific data which consistently show a high immunogenicity and efficacy of two doses of hepatitis b vaccine, the relevance of the second dose given at the age of 4 months is questionable. this study is designed to compare the immunogenicity of the hepatitis b component in children vaccinated with (i) two doses of infanrix-hexa administered at 2 and 12 months of age versus (ii) one dose of infanrix-hexa and one dose of twinrix administered respectively at 2 and 12 months of age versus (iii) three doses of infanrix-hexa administered at 2, 4 and 18 months of age (comparator).

Eligibility criteria:
inclusion criteria: * comparator group : * have received 3 doses of infanrix-hexa as part of the regular vaccination program at the age of 2, 4 and 18 months. • study groups: * have received 1 dose of infanrix-hexa as part of the regular vaccination program at the age of 2 months. exclusion criteria: * have received other doses of hepatitis b vaccine; * be considered immunosuppressed; * have an autoimmune disease; * have contraindications to hbv vaccination, as defined in the quebec immunization protocol; * have a bleeding disorder; * be significantly delayed in development; * have or plan to participate in other clinical studies with vaccines or products not approved in canada; * have presented a serious clinical condition to the vaccines administered as part of the study.

Keywords: vaccination two doses infants
spi-1005 in adults receiving cochlear implant

Conditions: Hearing Loss; Cochlear Trauma

Summary: the goal of this clinical trial is to learn about the effects of drug spi-1005 in adults receiving a cochlear implant with a long electrode array (flex26 or greater) from med-el cochlear implant systems into one ear. the main question this clinical trial aims to answer is: is drug spi-1005 safe and well-tolerated in adults receiving a cochlear implant, and/or what medical problems might participants experience when taking drug spi-1005? the clinical trial will also measure the effects of spi-1005 on hearing, word recognition, speech discrimination, tinnitus, and vertigo outcomes after receiving a cochlear implant. the purpose for this and future clinical trials is to learn whether spi-1005 can prevent or treat these side effects after receiving a cochlear implant. participants will take drug spi-1005 or placebo (a look-alike substance that contains no drug) for 6 months, starting 2 days before receiving the cochlear implant. there are 5 required in-clinic visits over 6 months for audiology and other tests. the effects of spi-1005 will be compared to the placebo (the look-alike substance that contains no drug) to study what effects spi-1005 might have.


Eligibility criteria:
inclusion criteria: * adults who are ≥18 years of age at time of consent. * post-lingual, bilateral, severe to profound sensorineural hearing loss scheduled to receive a long electrode array (flex26 or greater) from med-el cochlear implant systems into one ear. * air conduction thresholds (decibel hearing loss, db hl) at baseline in the ear scheduled to receive the cochlear implant: * ≥40 and ≤70 db hl at 125, 250, and 500 hz; and * ≥80 db hl at 2000 through 8000 hz. * willing and able to provide informed consent and to perform all behavioral tests as specified per-protocol, including pre-specified reproductive requirements. exclusion criteria: * current, or within 60 days prior to study enrollment, use of iv ototoxic medications such as chemotherapy including cisplatin, carboplatin, or oxaliplatin; aminoglycoside antibiotics including gentamicin, amikacin, tobramycin, kanamycin, or streptomycin; or loop diuretics including furosemide. * participation in another investigational drug or device study within 90 days prior to study enrollment. * female patients who are pregnant or breastfeeding. * air conduction thresholds at baseline in the ear scheduled to receive the cochlear implant with any no response at 125 through 8000 hz.

Keywords: hearing preservation cochlear implant spi-1005 ebselen
efficacy of monthly ibandronate in women with ra and reduced bone mineral density receiving long-term steroids

Conditions: Rheumatoid Arthritis; Osteoporosis; Osteopenia

Summary: this study was to investigate the efficacy of oral monthly ibandronate in the management of glucocorticoid induced osteoporosis in women with rheumatoid arthritis.

glucocorticoid therapy is associated with a number of significant side effects, of which bone loss resulting in glucocorticoid-induced osteoporosis and an increase in fracture risk is the most serious. however studies show that many patients treated with glucocorticoids do not receive treatment to prevent bone loss. there exist 5 large randomized controlled clinical trials providing evidence that the bisphosphonates etidronate, alendronate, and risedronate are effective in both the prevention and the treatment of glucocorticoid-induced osteoporosis. significant increases in bmd with bisphosphonate treatment, most consistently observed in lumbar spine, were seen in patients with many different glucocorticoid-treated disorders; most often ra and polymyalgia rheumatica, and occurred generally irrespective of patient age, sex and menopausal status in women. in addition, statically significant reductions in the absolute risk and relative risk of incident radiographic vertebral fractures were demonstrated after 1 year of treatment with risedronate. a similar significant reduction in the risk of incident radiographic vertebral fractures was seen in alendronate treated patients who completed 2 years of a study of alendronate in the prevention and treatment of glucocorticoid-induced osteoporosis. there exists a data about ibandronate which reported that intermittent intravenous ibandronate reduced vertebral fracture risk in corticosteroid-induced osteoporosis. however, there is no report about oral monthly ibandronate. current oral bisphosphonates, which are given either daily or weekly, are associated with stringent, inconvenient dosing schedules. less frequent dosing may provide great acceptability. the objective of this study was to investigate the efficacy of oral monthly ibandronate in women receiving long-term glucocorticoids.

Eligibility criteria:
inclusion criteria: * rheumatoid arthritis fulfilling the 1987 acr criteria * women equal and above 18 years, less than 75 years old * l1-4 t score less than -1.0 and equal or above -3.0 sd measured by dxa (dual energy x-ray absorptiometry) * patient must have taken prednisolone 5mg or its equivalent for more than 3 consecutive months within 1 year * patient who would be taking glucocorticoids for more than 3 months after enrollment exclusion criteria: * patient with vertebral fractures or nonvertebral fractures associated with osteoporosis * patient diagnosed with malignancy within 5 years * patient with endocrine dysfunction * ra functional class 4 * patient who took bisphosphonates within 6 months * patient on medication affecting bone mineral metabolism

Keywords: rheumatoid arthritis glucocorticoid induced osteoporosis vertebral fracture
effect of dried plum on bone and markers of bone status in men

Conditions: Osteoporosis; Osteopenia

Summary: the principal objective of this study is to examine whether the addition of 100 g dried plum to the diets of men, regardless of their bone status, positively influences their indices of bone turnover in comparison with their corresponding baseline values and the control regimen.

to test the bone protective properties of dried plum, 66 men (50 to 79 years of age) will receive either 100 g dried plum/day or a control regimen for 12 months. both groups will receive 500 mg calcium and 400 iu vitamin d daily. evaluation will be based on analyses of bone mineral density at baseline, 6 and 12-months and serum and urine markers of bone formation and resorption at baseline and 3, 6, and 12-months.

Eligibility criteria:
inclusion criteria: * healthy men (50-79 year-old) exclusion criteria: * endocrine (e.g., prednisone, other glucocorticoids) or neuroactive (e.g., dilantin, phenobarbital) drugs or any drugs known to influence bone and calcium metabolism * men whose bmd t-score at any site falls below 2.5 sd of the mean will be excluded from the study and referred to their primary care physician * subjects treated with calcitonin, bisphosphonates, raloxifene, sodium fluoride, anabolic agents, e.g. pth and growth hormone, or steroids for less than 3 months prior to the start of the study will be excluded. * body mass index (bmi) \ 30 will be excluded to avoid extremes in leanness/adiposity and to readily allow body composition assessment. * if subjects smoke 20 cigarettes or more per day, they will be excluded. * men who regularly consume dried plum or prune juice will not be accepted into the study.

Keywords: prunes dried plum nutrition bone
effect of methylprednisolone on systemic inflammatory response during pediatric congenital open-heart surgery

Conditions: Cyanotic Heart Disease; Cardiopulmonary Bypass

Summary: the goal of this study is to evaluate the effects of steroids on the early postoperative inflammatory response in patients undergoing elective pediatric congenital cardiac surgery, requiring cardiopulmonary bypass (cpb).


Eligibility criteria:
inclusion criteria: * children 1 month- 18 years of age * undergoing cardiac surgery for the first time and requiring cpb * surgeries for both cyatonic and acyanotic heart disease exclusion criteria: * pre-mature babies (\< 28 weeks at birth) * neonates * prior cardiac requiring cpb * surgeries requiring cpb \> 6 hours * surgeries requiring second run of cpb * patients requiring additional steroids during first 24 hours of cicu stay * patient expires within the initial 24 hours cicu stay. * compromised immune system - that is, known immunodeficiency or use of * immunomodulatory therapy. * peri-operative presence of two or more clinical or laboratory signs of active infection that were not attributable to any other cause: fever more than 100°f, heart rate or respiratory rate more than the normal range for age, white blood cell count more than 15% of the upper limit of normal, and an elevated c-reactive protein level above baseline. * preoperative mechanical ventilation, and preoperative need of inotropic agents or mechanical circulatory support. * patient already receiving steroids

Keywords: paediatric population
post static cold storage normothermic machine liver perfusion

Conditions: Liver Transplantation

Summary: the aim of this study is to assess the safety and feasibility of a short period of cold storage prior to normothermic machine perfusion in adult liver transplantation.


Eligibility criteria:
donor inclusion criteria: * donors over the age of 16 years. * liver allografts from donation after brain death (dbd), standard and extended criteria donors. (scd, ecd) and donation after circulatory death (dcd) donors. * liver must be perfused on organox metra perfusion device within 8 hours of in situ cold perfusion. * the perfusion should last a minimum of 4 hours and maximum of 24 hours. donor exclusion criteria: * living donors. * liver being transplanted as part of a multi-organ transplant (eg liver and kidney). * liver intended for split transplant. * donor age \<16 years * liver which investigator is unwilling to recruit to study. * any liver in which logistics prevent perfusion on the organox metra perfusion device within 8 hours of in situ cold perfusion. recipient inclusion criteria: * adult patients (18 years or more). * active on the waiting list for liver transplantation. * able to give informed consent. recipient exclusion criteria: * age less than 18 years. * acute/fulminant liver failure. * transplantation of more than one organ (e.g. liver and kidney). * refusal of informed consent. * unable to give informed consent.